PRACTICE PATTERNS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) RECEIVING TRANSARTERIAL CHEMOEMBOLIZATION (TACE): FINAL ANALYSIS OF OPTIMIS IN LATIN AMERICA

Introduction: OPTIMIS was a global, prospective, noninterventional study evaluating outcomes and practice patterns in patients with HCC treated with TACE, followed or not followed by sorafenib. Using protocolspecified criteria in the global cohort, we have observed longer OS in propensity score matched cohort with early start of sorafenib (16.2 months [n = 31)] versus those without (12.1 months [n = 62]). In order to understand local treatment patterns, we present results from Latin American patients from OPTIMIS. Methods: OPTIMIS enrolled patients with HCC for whom a decision to treat with TACE was made at study entry. TACE ineligibility was defined by study protocol-specified criteria and data were analyzed using descriptive statistics. Radiologic tumor response to each TACE treatment was determined by investigator assessment. Regional analysis of OPTIMIS was conducted in patients from Latin America, including baseline characteristics, TACE treatment patterns, and response rates. Results: Of the 1650 patients enrolled globally who received TACE, 19 were from Latin America (n = 12 Brazil, n = 7 Mexico). Of those, 5 patients (26%) were TACE ineligible at inclusion, 4 (21%) had an ECOG PS ≥1, 5 (26%) were BCLC C/D, and 7 (37%) were ChildPugh B/C. Nine patients (47%) received only 1 TACE, 6 (32%) had 2 TACE, and 4 (21%) received 35 TACE. Complete and partial response to first TACE was achieved by 10 patients (5 patients [26%] for each). Conclusions: In this real-world study, the results from Latin America were generally consistent with those reported globally. In Latin America and globally, a proportion of patients received TACE despite being ineligible at inclusion. Our data highlight the need to evaluate TACE practice in HCC to ensure patient eligibility for subsequent effective therapies. Clinical trial registration: NCT01933945